GlobeNewsWire
16 Jul 2026, 20:34 UTC · 2h ago
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
16 Jul 2026, 20:34 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
A judge denied ANI Pharmaceuticals' post-trial motions for a new trial and judgment as a matter of law regarding its dispute with CG Oncology. — A legal defeat at this stage reduces the immediate probability of the company recovering assets or royalties.
-0.60ANI Pharmaceuticals intends to appeal the ruling to the Delaware Supreme Court to seek a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec. — While an appeal keeps the possibility of future revenue alive, it extends the timeline of uncertainty and legal costs.
+0.20Which stocks this story touches
The company's post-trial motions were denied by a judge, though it intends to appeal to recover assets and royalties.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
10h ago
